The short answer: eligibility is not one switch
Google's publisher rules do not ban a page merely because it discusses diabetes. They separate three questions: whether the content is prohibited, whether the page carries a publisher-restriction label, and whether you may use health information to personalize ads. A page can be acceptable for non-personalized serving and still be unsuitable for audience targeting. One problem calls for removing content, another for accepting lower bids, and the third for separating health-status data from ad personalization.
Gate 1: What the page may say and sell
Google-served ads cannot appear on content promoting harmful health claims, or on content about an ongoing major health crisis that contradicts authoritative scientific consensus. Examples include anti-vaccine content, denial that AIDS or COVID-19 exists, and sexual-orientation conversion therapy. No diabetes-specific example is listed, so cure or reversal promises and copy that contradicts consensus guidance create risk; a reviewer decides whether a page crosses the line. Pages violating Web Search spam policies, containing a misleading experience, or containing malware are also outside the ad code.
Prescription drugs are a separate prohibited category: facilitating online sales, such as selling prescription drugs or running an online pharmacy. An Rx checkout or pharmacy front on the monetized page falls inside it.
Supplements need a separate audit. Promoting unapproved drugs and supplements is prohibited, including products on a non-exhaustive list, ephedra-containing products, herbal or dietary supplements with active pharmaceutical or dangerous ingredients, and drug-like names that confuse. Check bundle offers against the linked list (support.google.com/adspolicy/answer/2423645); a headline fix does not cure an offer inside the policy.
Identity and promotion rules also apply. Misrepresenting or concealing information about the publisher, content creator, content purpose, or the content itself is a violation; so is falsely implying endorsement by another person, organization, product, or service. Using false, misleading, or deceptive information to promote content, products, or services is prohibited; the policy cites get-rich-quick schemes. State who runs the program accurately, avoid borrowed logos, and examine outcome claims under this rule.
Gate 2: Whether you can personalize ads
The sensitive-information clause is often misread. Google's publisher privacy rules (support.google.com/adsense/answer/10502938) bar using ad products or ad code to select or personalize ads, and bar collecting or using cookie lists and audience data, based on inferred or actual sensitive information. The policy includes health/medical records or information, such as information in sites or apps marketing to specific health-condition groups. It governs ad selection and audience use, not the page's topic; that reading is interpretation, not a verbatim allowance for contextual ads.
A remarketing list built from visitors to a diabetes program page, or a segment labeled "people with diabetes," is audience data tied to health status. Treat it as inside the restricted basis. If personalization remains, personalized ads require rights to audience data, an in-ad interest-based notice (for example, the AdChoices icon), and compliance with Digital Advertising Alliance principles.
Gate 3: Restriction label or policy violation?
Google distinguishes publisher restrictions from policy violations. Restricted content can still carry AdSense code, but fewer ad sources bid; sometimes no ads show, and Google Ads does not serve there. Prohibited content is different: Google-served ads are not permitted. Similar diabetes pages can behave differently: one shows fewer ads after cleanup because it is restricted; another shows none because its claims or offers are prohibited.
The retrieved material does not say whether a given page will be labeled restricted or prohibited; Google reviewers decide on the actual page. Clean the page, then request review if you are in AdSense; no outcome or timeline is guaranteed.
Penalty guidance reviewed here counts five normal violations as one strike and one egregious violation as one strike; egregious factors include scale, deception, and advertiser harm.
If you host exercise or cooking videos with ad units, keep controls visible and respect the one-video-with-sound and 50% in-view autoplay rules.
Four policy areas at a glance
| Policy area | What the text covers | Implication for a diabetes page | Consequence stated |
|---|
| Sensitive health information in personalized ads | Health data used to target ads or build audience lists | Diabetes-status lists fall inside the restricted basis | Prohibition on use; enforcement outcome not stated |
| Harmful health claims in page content | Harmful claims or crisis content contradicting consensus | Cure promises and consensus-contradicting copy create risk | Ads not permitted |
| Prescription drugs and unapproved products | Online Rx sales; unapproved drugs and supplements | Rx checkout, pharmacy front, or drug-like supplement stack | Ads not permitted |
| Publisher restriction label | Code can remain, but fewer sources bid | Expect reduced fill or no ads after cleanup | Fewer or no ads |
Read by consequence, not topic: the first row limits personalization, the next two are content prohibitions, and the fourth limits bid competition rather than ad code.
A pre-flight fix sequence
- Rewrite cure/reversal promises and consensus-contradicting copy; avoid clinical outcome claims.
- Remove Rx checkout, pharmacy links, and storefront functions.
- Audit supplement offers against the linked unapproved list, including ephedra, active or dangerous ingredients, and confusing names.
- State the operator and program accurately; remove implied clinic, insurer, or Google endorsement.
- Add a privacy policy disclosing Google-related data collection, sharing, and use, including cookies, web beacons, IP addresses, or other identifiers; link to Google's "How Google uses data" page.
- Keep health-status audiences out of personalization; if any remains, secure audience-data rights, show interest-based ad notice, and follow DAA principles.
What this article cannot decide
None of the retrieved material contains diabetes clinical, programmatic, or reimbursement evidence, so this article cannot support outcome, staffing, accreditation, coverage, or cost claims. It cannot predict approval, restriction, or strike outcomes. Policy text changes; the live help pages govern, and the text here was supplied in translation, so check English wording. Eligibility is decided by reviewers on the actual page. This is not legal, medical, or regulatory advice; consult qualified professionals.
Fix the claims and offers first, then re-check personalization. That is the sequence the policy text supports.